Back to Newsroom
Back to Newsroom

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HNST, BMRN and AMRN

Sunday, 07 November 2021 10:45 AM

The Klein Law Firm

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / November 7, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

The Honest Company, Inc. (NASDAQ:HNST)
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Honest common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's May 2021 initial public offering.
Lead Plaintiff Deadline: November 15, 2021

The HNST lawsuit alleges The Honest Company, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) prior to the Initial Public Offering ("IPO"), the Company's results had been significantly impacted by a multimillion-dollar COVID-19 stock-up for products in the Diapers and Wipes category and Household and Wellness category; (2) at the time of the IPO, the Company was experiencing decelerating demand for such products; (3) as a result, the Company's financial results would likely be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in HNST: https://www.kleinstocklaw.com/pslra-1/the-honest-company-inc-loss-submission-form?id=20924&from=1

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Class Period: January 13, 2020 - September 3, 2021
Lead Plaintiff Deadline: December 22, 2021

Throughout the class period, BioMarin Pharmaceutical Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase, was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the Food and Drug Administration would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in BMRN: https://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?id=20924&from=1

Amarin Corporation Plc (NASDAQ:AMRN)
Class Period: December 5, 2018 - June 21, 2021
Lead Plaintiff Deadline: December 23, 2021

The complaint alleges Amarin Corporation Plc made materially false and/or misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (ii) once the District Court invalidated certain of Amarin's patents, there was little to no chance of reversing that ruling; (iii) the Company's litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the Company's business and future prospects; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in AMRN: https://www.kleinstocklaw.com/pslra-1/amarin-corporation-plc-loss-submission-form?id=20924&from=1

The Klein Law Firm, Sunday, November 7, 2021, Press release picture

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: